- Home
- KURA vs REPL Comparison
KURA vs REPL Comparison
Compare KURA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | REPL |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.0M | 692.8M |
| IPO Year | 2015 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KURA | REPL |
|---|---|---|
| Price | $8.49 | $8.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $25.88 | $11.13 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $25.83 | N/A |
| Revenue Next Year | $103.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $5.45 | $2.68 |
| 52 Week High | $12.49 | $13.24 |
Technical Indicators
Market Signals| Indicator | KURA | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 63.50 |
| Support Level | $7.99 | $8.24 |
| Resistance Level | $10.50 | $8.82 |
| Average True Range (ATR) | 0.41 | 0.50 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 68.57 | 87.02 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.